Shanghai Newsummit Biopharma Group Co., Ltd
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Newsummit Biopharma Group Co., Ltd
Tech Transfer Roundup: Ohio State Turns To Industry Exec To Optimize Assets Before A Deal
Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.
Deals Shaping The Medical Industry, April 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Newsummit Biopharma Holdings Ltd.
- Shanghai Newsummit Group
- Shanghai Newsummit Biopharma Co., Ltd
- Shanghai Newsummit Co.,
- Newsummit Biopharma Holdings Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice